Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue tetravalent vaccine (live, attenuated) (Takeda)
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Qdenga (TAK-003) is a live-attenuated tetravalent dengue vaccine developed by Takeda. It is constructed using a live-attenuated dengue serotype 2 virus (DENV-2) as the genetic backbone. The vaccine contains attenuated strains for all four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). For serotypes 1, 3, and 4, the pre-membrane (prM) and envelope (E) genes of DENV-2 are replaced with those of the other serotypes, creating chimeric viruses, while the DENV-2 component is the attenuated parent strain itself. Qdenga is designed to elicit both humoral and cellular immune responses against all four serotypes in both dengue-naive and dengue-exposed individuals. It is administered subcutaneously in a two-dose regimen and has been approved in multiple regions, including the European Union, the United Kingdom, Indonesia, and Brazil, for the prevention of dengue disease caused by any of the four serotypes.
- Brand names
- Qdenga
- Other names
- Takeda dengue vaccineDENVax
02
Targets
Dengue virus envelope proteinDengue virus nonstructural protein (DENV NS protein)prM (Dengue virus pre-membrane protein)
Beyond the preview
Go deeper on dengue tetravalent vaccine (live, attenuated) (Takeda).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue tetravalent vaccine (live, attenuated) (Takeda).